Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
Elias AD, Spoelstra NS, Staley AW, Sams S, Crump LS, Vidal GA, Borges VF, Kabos P, Diamond JR, Shagisultanova E, Afghahi A, Mayordomo J, McSpadden T, Crawford G, D'Alessandro A, Zolman KL, van Bokhoven A, Zhuang Y, Gallagher RI, Wulfkuhle JD, Petricoin Iii EF, Gao D, Richer JK. Elias AD, et al. Among authors: shagisultanova e. NPJ Breast Cancer. 2023 May 20;9(1):41. doi: 10.1038/s41523-023-00544-z. NPJ Breast Cancer. 2023. PMID: 37210417 Free PMC article.
Triple-negative breast cancer in the elderly.
Shagisultanova E, Mayordomo J, Elias AD. Shagisultanova E, et al. Breast J. 2017 Nov;23(6):627-629. doi: 10.1111/tbj.12814. Breast J. 2017. PMID: 29112794 No abstract available.
Combined inhibition of Aurora A and p21-activated kinase 1 as a new treatment strategy in breast cancer.
Korobeynikov V, Borakove M, Feng Y, Wuest WM, Koval AB, Nikonova AS, Serebriiskii I, Chernoff J, Borges VF, Golemis EA, Shagisultanova E. Korobeynikov V, et al. Among authors: shagisultanova e. Breast Cancer Res Treat. 2019 Sep;177(2):369-382. doi: 10.1007/s10549-019-05329-2. Epub 2019 Jun 28. Breast Cancer Res Treat. 2019. PMID: 31254157 Free PMC article.
Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: A retrospective matched cohort study.
West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE. West AH, et al. Among authors: shagisultanova e. Cancer Med. 2019 Sep;8(12):5609-5618. doi: 10.1002/cam4.2471. Epub 2019 Aug 12. Cancer Med. 2019. PMID: 31407530 Free PMC article.
Real-world evidence from a University Hospital system regarding the uptake of adjuvant pertuzumab and/or neratinib before and after their FDA approval.
Stoen E, Kagihara J, Shagisultanova E, Fisher CM, Nicklawsky A, Kabos P, Borges VF, Diamond JR. Stoen E, et al. Among authors: shagisultanova e. Breast Cancer Res Treat. 2021 Jun;187(3):883-891. doi: 10.1007/s10549-021-06132-8. Epub 2021 Feb 24. Breast Cancer Res Treat. 2021. PMID: 33625615 Free PMC article.
Moving Towards Targeted Therapies for Triple-Negative Breast Cancer.
Kagihara JA, Shagisultanova E, Afghahi A, Diamond JR. Kagihara JA, et al. Among authors: shagisultanova e. Curr Breast Cancer Rep. 2021 Sep;13(3):216-226. doi: 10.1007/s12609-021-00416-0. Epub 2021 May 4. Curr Breast Cancer Rep. 2021. PMID: 34457184 Free PMC article.
28 results